Anita P. Rahman, Pharm.D., BCPS

Reportable Conflicts of Interests:  None

Disclosure of Financial Conflicts of Interest: None

Education:
Doctor of Pharmacy
University of Houston
College of Pharmacy

Pre-requisites
University of North Texas

Post Graduate or Residency Training:

Internal Medicine Specialty Resident

Veterans Affairs North Texas Health Care System

Texas Tech University Health Sciences Center

School of Pharmacy Dallas/Fort Worth Regional Campus

Pharmacy Practice Resident
ASHP Accredited Pharmacy Residency Program
Veterans Affairs North Texas Health Care System
Dallas/Fort Worth Regional Campus

Fellowship and Board Certifications:         
Advanced Cardiac Life Support Provider
American Heart Association

Basic Life Support Healthcare Provider

American Heart Association

Pharmacy Preceptor Certificate
Texas State Board of Pharmacy

Board Certified Pharmacotherapy
Board of Pharmaceutical Specialties

Current Position or Practice Site:                   
Internal Medicine Clinical Pharmacy Specialist
Parkland Health & Hospital System
Dallas, TX

Past Positions and/or Appointments:                       

Assistant Clinical Instructor
Texas Tech University Health Sciences Center
School of Pharmacy
Dallas/Fort Worth Regional Campus

Staff Pharmacist
Walgreen’s Pharmacy
Carrollton, Texas

Publications:                                                       
Rahman AP, Easton SA, Nguyen ST, Bain AM, Payne KD, Bedimo R, Busti, AJ. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy.Pharmacotherapy. 2008 Jul;28(7):913-9

Bain AM, White EA, Rutherford WS, Rahman AP, Busti AJ.  A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature. Pharmacotherapy. 2008 Jul;28(7):932-8

Hall RG II, Payne KD, Bain AM, Rahman AP, Nguyen ST, Eaton SA, Busti AJ, Vu SL, Bedimo R. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med. 2008 Jun;121(6):515-8.

Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Pharmacotherapy. 2008 Mar;28(3):323-30.

(Last updated: 2/9/2009)